Gene therapy in systemic lupus erythematosus

Current Gene Therapy

Volumn 5, Issue 6, 2005, Pages 677-684

  Kyttaris, V C ^a,b   Sfikakis, P P ^c   Juang, Y T ^a,d   Tsokos, G C ^a,d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Cell therapy; Cytokines; Gene therapy; Genetics; SLE

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GONADORELIN; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 4 ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE (CALCIUM,CALMODULIN); T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTING CELL; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; EX VIVO STUDY; FEASIBILITY STUDY; GENE TARGETING; GENE TRANSFER; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHENOTYPE; PLASMID; REVIEW; SIALOADENITIS; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CHEMOKINES; GENE THERAPY; GENETIC ENGINEERING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, ANIMAL; T-LYMPHOCYTES;

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS;

EID: 29444443229     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652305774964703     Document Type: Review

References (52)

1. Ansari, M. A., M. Dhar, V. Muthukrishnan, T. L. Morton, N. Bakht and J. D. Jacobson. (2003) Administration of antisense oligonucleotides to Galpha(Q/11) reduces the severity of murine lupus. Biochimie., 85: 627-32.
2. Arnett, F. C., J. D. Reveille, R. W. Wilson, T. T. Provost and W. B. Bias. (1984) Systemic lupus erythematosus: current state of the genetic hypothesis. Semin Arthritis Rheum., 14: 24-35.
3. Balow, J. E., D. T. Boumpas and H. A. Austin, 3rd. (2000) New prospects for treatment of lupus nephritis. Semin Nephrol., 20: 32-9.
4. Boumpas, D. T., H. A. Austin, III, B. J. Fessler, J. E. Balow, J. H. Klippel and M. D. Lockshin. (1995) Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Annals of Internal Med., 122: 940-950.
5. Boumpas, D. T., B. J. Fessler, H. A. Austin, III, J. E. Balow, J. H. Klippel and M. D. Lockshin. (1995) Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Annals of Internal Med., 123: 42-53.
6. Browness, P., K. A. Davies, P. J. Norsworthy, P. Athanassiou, W. Tylor, L. K. Borysiewicz, P. A. Meyer and M. J. Walport. (1994) Hereditary C1q deficiency and systemic lupus erythematosus. QMJ, 87: 455-464.
7. Chang, Y. and G. J. Prud'homme. (1999) Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J. Gene Med., 1: 415-23.
8. Choi, E. W., I. S. Shin, H. Y. Youn, D. Y. Kim, H. Lee, Y. J. Chae and C. W. Lee. (2005) Gene therapy using non-viral peptide vector in a canine systemic lupus erythematosus model. Vet. Immunol. Immunopathol., 103: 223-33.
9. Deapen, D., A. Escalante, L. Weinrib, D. Horwitz, B. Bachman, P. Roy-Burman, A. Walker and T. M. Mack. (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum., 35: 311-318.
10. Edberg, J. C., C. D. Langfeld, J. Wu, K. Moser, K. Kaufman, J. Kelly, V. Bansal, M. Brown, J. E. Salmon, S. Rich, J. B. Harley and R. P. Kimberly. (2002) Genetic Linkage and association of Fcγ Receptor IIIA. (CD16A) on Chromosome 1q23 with human Systemic Lupus Erythematosus. Arthritis Rheum., 46: 2132-2140.
11. Enyedy, E. J., M. P. Nambiar, S. N. Liossis, G. Dennis, G. M. Kammer and G. C. Tsokos. (2001) Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum., 44: 1114-21.
12. Fleck, M., H. G. Zhang, E. R. Kern, H. C. Hsu, U. Muller-Ladner and J. D. Mountz. (2001) Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum., 44: 964-73.
13. Fujio, K., A. Okamoto, H. Tahara, M. Abe, Y. Jiang, T. Kitamura, S. Hirose and K. Yamamoto. (2004) Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. J. Immunol., 173: 2118-25.
14. Gutierrez-Ramos, J. C., J. L. Andreu, Y. Revilla, E. Vinuela and C. Martinez-A. (1990) Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. 346: 271-274.
15. Hawn, T. R., H. Wu, J. M. Grossman, B. H. Hahn, B. P. Tsao and A. Aderem. (2005) A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA, 102: 10593-7.
16. Howard, P. F., M. C. Hochberg, W. B. Bias, F. C. Arnett and R. H. McClean. (1986) Relationship between C4 null genes, HLA-D region antigens and genetic susceptibility to systemic lupus erythematosus in Caucasian and black Americans. Am. J. Med., 81: 187-193.
17. Huggins, M. L., F. P. Huang, D. Xu, G. Lindop and D. I. Stott. (1999) Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus, 8: 29-38.
18. Juang, Y. T., Y. Wang, E. E. Solomou, Y. Li, C. Mawrin, K. Tenbrock, V. C. Kyttaris and G. C. Tsokos. (2005) Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest., 115: 996-1005.
19. Kyttaris, V. and G. Tsokos. (2003) Uncovering the genetics of systemic lupus erythematosus: implications for therapy. Am. J. Pharmacogenomics, 3: 193-202.
20. Kyttaris, V. C., Y. T. Juang, K. Tenbrock, A. Weinstein and G. C. Tsokos. (2004) Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol., 173: 3557-63.
21. Kyttaris, V. C. and G. C. Tsokos. (2004) T lymphocytes in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol., 16: 548-52.
22. Lawrence, J. S., C. L. Martins and G. L. Drake. (1987) A family survey of lupus erythematosus. Heritability. J. Rheumatol., 14: 913.
23. Lawson, B. R., G. J. Prud'homme, Y. Chang, H. A. Gardner, J. Kuan, D. H. Kono and A. N. Theofilopoulos. (2000) Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J. Clin. Invest., 106: 207-15.
24. Liossis, S. N., X. Z. Ding, G. J. Dennis and G. C. Tsokos. (1998) Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J. Clin. Invest., 101: 1448-57.
25. Liossis, S. N., P. P. Sfikakis and G. C. Tsokos. (1998) Immune cell signaling aberrations in human lupus. Immunol. Res., 18: 27-39.
26. Liu, W., A. Szalai, L. Zhao, D. Liu, F. Martin, R. P. Kimberly, T. Zhou and R. H. Carter. (2004) Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum., 50: 1884-96.
27. Malek, T. R. and A. L. Bayer. (2004) Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol., 4: 665-74.
28. Mangia, A., R. Santoro, N. Minerva, G. L. Ricci, V. Carretta, M. Persico, F. Vinelli, G. Scotto, D. Bacca, M. Annese, M. Romano, F. Zechini, F. Sogari, F. Spirito and A. Andriulli. (2005) Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. N. Engl. J. Med., 352: 2609-2617.
29. McCarty, D. J., S. Manzi, T. A. Medsger, Jr and et al. (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum., 38: 1260-1270.
30. Nambiar, M. P., C. U. Fisher, V. G. Warke, S. Krishnan, J. P. Mitchell, N. Delaney and G. C. Tsokos. (2003) Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum., 48: 1948-55.
31. Olsen, N. J. and C. M. Stein. (2004) New Drugs for Rheumatoid Arthritis. N. Engl. J. Med., 350: 2167-2179.
32. Petri, M.. (2004) Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus, 13: 366-71.
33. Pickering, M. C., M. Botto, P. R. Taylor, P. J. Lachmann and M. J. Walport. (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol., 76: 227-324.
34. Prokunina, L., C. Castillejo-Lopez, F. Oberg, I. Gunnarsson, L. Berg, V. Magnusson, A. Brookes, D. Tentler, H. Kristjansdottir, G. Grondal, A. Bolstad, E. Svenungsson, I. Lundberg, G. Sturfelt, A. Jonssen, L. Truedsson, G. Lima, J. Alcocer-Varela, R. Jonsson, U. B. Gyllensten, J. B. Harley, D. Alarcon-Segovia, K. Steinsson and M. E. Alarcon-Riquelme. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genetics, 32: 666-669.
35. Prud'homme, G. J. and Y. Chang. (1999) Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther., 6: 771-7.
36. Prud'homme, G. J., D. H. Kono and A. N. Theofilopoulos. (1995) Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol. Immunol., 32: 495-503.
37. Raz, E., J. Dudler, M. Lotz, S. M. Baird, C. C. Berry, R. A. Eisenberg and D. A. Carson. (1995) Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus, 4: 286-92.
38. Salmon JE and Pricop L. (2001) Human Receptors of Immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum., 44: 739-750.
39. Salmon, J. E., S. Millard, L. A. Schachter, F. C. Arnett, E. M. Ginzler, M. F. Gourley, R. Reamsey-Goldman, M. G. E. Peterson and R. P. Kimberly. (1996) Fc gamma RIIA alleles are heritable risk for SLE nephritis in African Americans. J. Clin. Invest., 97: 1348-1354.
40. Shimizu, S., H. Nakashima, K. Masutani, Y. Inoue, K. Miyake, M. Akahoshi, Y. Tanaka, K. Egashira, H. Hirakata, T. Otsuka and M. Harada. (2004) Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology, (Oxford), 43: 1121-8.
41. Solomou, E. E., Y. T. Juang, M. F. Gourley, G. M. Kammer and G. C. Tsokos. (2001) Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol., 166: 4216-22.
42. Tenbrock, K., Y. T. Juang, M. F. Gourley, M. P. Nambiar and G. C. Tsokos. (2002) Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J. Immunol., 169: 4147-52.
43. Tenbrock, K., Y. T. Juang, M. Tolnay and G. C. Tsokos. (2003) The cyclic adenosine 5′-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J. Immunol., 170: 2971-6.
44. Trucco, M., P. D. Robbins, A. W. Thomson and N. Giannoukakis. (2002) Gene therapy strategies to prevent autoimmune disorders. Curr. Gene Ther., 2: 341-54.
45. Tsao, B. P., R. M. Cantor, M. Grossman and et al. (1999) PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. J. Clin. Invest., 103: 1135-1140.
46. Tsokos, G. C.. (1999). Overview of cellular immune function in systemic lupus erythematosus. In: Systemic lupus erythematosus. R. G. Lahita. Academic Press, New York: pp17-54.
47. Tsokos, G. C. and D. T. Boumpas. (2001). Systemic Lupus Erythematosus. In: Molecular Pathology of Autoimmunity. Theofilopoulos A and Bona C. Taylor and Francis, Ann Arbor, MI: pp255-281.
48. Tsokos, G. C. and S.-N. C. Liossis. (1999) Immune cell signaling defects in lupus: activation, anergy and death. Immunol. Today, 20: 119-124.
49. Tsokos, G. C., M. P. Nambiar, K. Tenbrock and Y. T. Juang. (2003) Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol., 24: 259-63.
50. Zhang, H.-G., M. Fleck, E. R. Kern, D. Liu, Y. Wang, H.-C. Hsu, P. Yang, Z. Wang, D. T. Curiel, T. Zhou and J. D. Mountz. (2000) Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J. Clin. Invest., 105: 813-821.
51. Zhang, H.-g., X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C. K. Edwards, H. Bluethmann, J. D. Mountz and T. Zhou. (1999) Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells. J. Immunol., 162: 1423-1430.
52. Zhang, J., V. Roschke, K. P. Baker, Z. Wang, G. S. Alarcon, B. J. Fessler, H. Bastian, R. P. Kimberly and T. Zhou. (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol., 166: 6-10.